Close
Smartlab Europe
Inizio Ignite

Watson introduces generic version of Fortamet

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

AstraZeneca Breztri Reports Positive Phase III Trial Results

Results from the Phase III KALOS and LOGOS trials...

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...
- Advertisement -
Smart Lab Europe

Watson Pharmaceuticals has introduced an authorized generic version of Fortamet as a part of an agreement with Shionogi.

The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an adjunct to diet and exercise to lower blood glucose for patients 17 years of age or older. Fortamet had combined brand and generic sales of approximately $82m for the twelve months ending 28 February 2012, according to IMS Health data.

Smart Lab Europe

Latest stories

Related stories

AstraZeneca Breztri Reports Positive Phase III Trial Results

Results from the Phase III KALOS and LOGOS trials...

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »